Vericel Corp at JPMorgan Healthcare Conference Transcript
Good morning. Welcome, everyone, to the third day of the 41st JPMorgan Conference. Here we go. We're thrilled to have you here, and we're thrilled to have the Vericel team as well. We've got Nick Colangelo, President and CEO, here to present. I'll go ahead and pass it over to Nick.
Okay. Well, thanks, [James]. It's great to be here today. And before I begin, I just want to remind everyone that this presentation contains forward-looking statements, and you should refer to our documents on file with the SEC for further information.
So for those of you who are not as familiar with our company, Vericel is a leader in advanced therapies for the sports medicine and the severe burn care markets. We have a portfolio of highly innovative advanced cell therapies and specialty biologics that are really focused on changing the standard of care for patients with cartilage injuries and severe burns.
We currently market 2 products in the United States. They're both
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |